Bayer unit BlueRock wins FDA and EMA orphan drug designations for OpCT-001
BlueRock, a Bayer unit, received FDA orphan drug status for lemiretprocel (OpCT-001) in primary photoreceptor diseases, and the EMA also granted an orphan designation.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.